Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial

in Ann Arbor, Michigan, and the Mayo Clinic in Rochester, Minnesota.

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit

This press release contains forward-looking statements, within the

meaning of Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements, including the Company's expectations

related to the U.S. Phase II sarcoma clinical trial and the Company's

belief as to the potential of REOLYSIN(R) as a cancer therapeutic,

involve known and unknown risks and uncertainties, which could cause the

Company's ac

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
(Date:7/10/2014)... sit upside down forever. Nanophysics makes sure of that. Mechanics ... just published in Physical Review E . Knowledge that ... that seem to be able to sit still forever, and ... years. We will soon be able to buy smart new ... But the fact is, sooner or later the grip is ...
(Date:1/15/2014)... , Using an approach akin to assembling a ... Standards and Technology (NIST) researchers have succeeded in ... reduces the flammability of foam commonly used in ... flammability of the nanotube-coated polyurethane foam was reduced ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... DIEGO, CA, July 7, 2008 Senomyx, Inc.,(Nasdaq: ... using proprietary technologies,to discover and develop novel flavor ... announced today a one-year extension of its,exclusive collaborative ... a unit of Cadbury plc, for the discovery ...
... Bernard Barataud, EVRY, France, July 7 The ... head the laboratory created in 1990 by the AFM,(French ... has decided to hand over the reins after heading ... and 2008., Yves Champey is a physician by ...
... The Eniva Research Group has,released results ... Pauling,Micronutrient Research Institute at Oregon State University ... DNA protective,anti-mutagenic activity for human cells. This ... an ongoing investigative effort to further identify,mechanisms ...
Cached Biology Technology:SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC 2SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC 3A New President at the Head of the Genethon Laboratory 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2
(Date:7/10/2014)... housed at NJIT,s business incubator, received a $1.4 million ... will use to staunch bleeding during brain surgery. , ... and the natural bio-polymer solutions in the gel will ... seconds. , The gel can shorten an intracranial ... less time for the patient,s skull to be open ...
(Date:7/10/2014)... a family of enzymes known as heme enzymes, due ... active site. At the centre of the heme cofactor ... when a reacting heme is in an intermediate state ... for decades is whether this oxidation involves just an ... this fundamental question has implications for understanding oxidative processes ...
(Date:7/10/2014)... The American Chemical Society (ACS) announced today that ... journal ACS Infectious Diseases as editor-in-chief. ... January 2015, the pioneering journal will meet a ... chemistry-focused infectious diseases research. , "Our vision is ... a strong emphasis on the basic science that ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3ACS Infectious Diseases: Unique chemistry journal names editor 2
... discovered on an unexplored mountain range in northern ... Conservation Programme. It was named "Yariguies Brush-Finch," with ... The new brush-finch was described by an Anglo-Colombian ... and Blanca Huertas (Natural History Museum and University ...
... New research identifies an important gene that influences several ... study, funded by National Institutes of Drug Abuse, was ... Meeting. , Investigator Marina Picciotto, PhD, associate professor ... that nicotine can increase activity of a molecule called ...
... the Chlamydia bacterium, which causes a sexually transmitted disease ... evolutionary heritage, which is not found in most other ... an effective cure for Chlamydia infections. , "The unique ... proposed by others," said Thomas Leustek," a professor in ...
Cached Biology News:New bird discovered on unexplored Columbian mountain 2New research identifies gene important for nicotine's effects on the brain 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 3
... Characteristics:, Antibody Binding: High, 400 ng ... volume) , Binding Interaction: Hydrophobic/Ionic , Performance ... (bottom): Flat , Maximum Well Volume: 360 ... tray ,Features, Special optically clear ...
... enables early selection of the best ... quantitative data for sensitivity, dynamic range, ... Furthermore quantitative antibody fingerprints can be ... your antibodies., The full-service package includes ...
Biology Products: